141 results about "Inhibitory peptide" patented technology

The invention belongs to the field of skin care products, and particularly relates to an anti-wrinkle and anti-aging composition as well as a preparation method and application thereof, and the anti-wrinkle and anti-aging composition comprises neurotransmitter inhibition peptide, signal peptide, madecassoside, inositol and glycosylglycerol. The neurotransmitter inhibition type peptide is at least three of acetyl hexapeptide-8, arginine / lysine polypeptide, dipeptide diaminobutyrylbenzylamide diacetate and acetyl octapeptide-3, and the signal type peptide is at least two of palmitoyl pentapeptide-4, decapeptide-4 and acetyl tetrapeptide-9. Compared with the prior art, all the components of the anti-wrinkle and anti-aging composition act on different anti-aging pathways and can be matched with one another from multiple aspects of oxidation resistance, inflammation resistance, moisturizing, cell viability enhancement, wrinkle reduction and the like, a more comprehensive and better anti-aging effect is provided, skin aging is comprehensively resisted, the skin is in a more young state, and the anti-wrinkle and anti-aging composition has the advantages that the anti-wrinkle and anti-aging effects are achieved. And the anti-wrinkle and anti-aging composition is small in irritation and good in stability.

The invention discloses a scallop skirt ACE inhibitory peptide activity method and system based on deep learning, and relates to the technical field of bioengineering.The scallop skirt ACE inhibitory peptide activity method comprises the steps that a comprehensive data set is obtained based on simulated in-vivo test data and peptide level feature data of different peptides, key features are screened, and a training set and a test set are divided; initializing a random forest model, an SVM model and a logistic regression model, performing independent training by using the training set, and determining an optimal prediction model of the peptide antihypertensive activity based on a prediction result of the test set; extracting importance data of key features based on the optimal prediction model for the antihypertensive activity of the peptide, sorting the importance data, and visually analyzing the antihypertensive activity features, feature importance sorting and model performance of different peptides; and all key results in the analysis process are integrated and systematically stored. According to the method, normal form reference with prediction accuracy and mechanism depth can be provided for clinical transformation of marine bioactive peptides, and AI-driven novel peptide drug research and development are promoted to enter a new stage.

The present invention relates to the field of protein engineering, and specifically relates to a Morchella esculenta peptide and the use thereof. By means of comprehensively applying bioinformatic methods such as virtual enzymolysis, activity prediction, physicochemical property and safety evaluation, and molecular docking, one Morchella esculenta peptide having the potential effects of "inhibiting oxidation + skin whitening" is screened from Morchella esculenta, which peptide has a sequence of WWVCAK. In-vitro chemical experiments verify that WWVCAK is the most effective antioxidant and tyrosinase-inhibitory peptide. Therefore, WWVCAK can exert the effects of inhibting oxidation and skin whitening via multiple targets, multiple functions and multiple pathways. WWVCAK is expected to be developed and used in cosmetics as a functional skin-care ingredient with the twin effects of "inhibiting oxidation + skin whitening".

The application discloses a Vibrio parahaemolyticus quorum sensing inhibiting peptide and application thereof, and belongs to the field of bioactive peptides. The inhibiting peptide comprises the following amino acid sequence: Ser-Phe; the application further discloses application of the quorum sensing inhibiting peptide in inhibiting Vibrio parahaemolyticus or preparing antibacterial drugs for inhibiting Vibrio parahaemolyticus. The application adopts a molecular docking technology to screen an active peptide having an inhibiting effect on a Vibrio parahaemolyticus LuxS / AI-2 quorum sensing system, ADMET property prediction is carried out on a peptide segment with better binding force, and finally, a bioactive peptide SF stably combined with LuxP, LuxQ and LuxS is obtained; the dipeptide has good in-vitro inhibiting activity on the Vibrio parahaemolyticus LuxS / AI-2 quorum sensing, and has no cytotoxicity. The dipeptide obtained by the application can be used for guiding development of a new type of antibacterial preparation applied to food, medicine and agriculture and other fields, and has great significance for human health and agricultural development.

The invention discloses goat milk with hypoglycemic activity and a preparation method thereof, and belongs to the technical field of enzyme engineering. The goat milk is used as a raw material, enzymolysis goat milk with alpha-G inhibitory activity is obtained through compound protease hydrolysis, it is found that the enzymolysis goat milk has hypoglycemic activity, and the goat milk powder with the hypoglycemic activity is further prepared through spray drying. The alpha-G inhibitory peptides in the enzymolysis goat milk are separated and identified, 20 alpha-G inhibitory peptides are found from components with the highest alpha-G inhibition rate, the molecular weight of the alpha-G inhibitory peptides is 377-962 Da, and the alpha-G inhibitory peptides are mainly derived from beta-casein, alpha S1-casein, alpha S2-casein, kappa-casein, beta-lactoglobulin, lactoglobulin and osteopontin of the goat milk. The alpha-G inhibitory peptide is prepared by hydrolyzing the goat milk through the compound enzyme, the amino acid sequence of the alpha-G inhibitory peptide is separated and identified, the goat milk with hypoglycemic activity is developed, and theoretical basis and technical support are provided for subsequent development of hypoglycemic dairy products.

The invention relates to synthetic peptides of no more than 20 amino acids in size useful in the treatment of cancer.

The application belongs to the technical field of biotechnology, and particularly relates to application of albumin polypeptide gel beads in a product for treating or preventing sarcopenia. Egg white protein is used as raw material to extract protein, and albumin dipeptide-based peptidase-IV inhibitory peptide is prepared through a biological enzymolysis method. Bioinformatics analysis is used to screen out the inhibitory peptide TPYMFP, and the IC50 value of the inhibitory peptide TPYMFP for dipeptide-based peptidase-IV reaches 3.12 ± 0.49 mmol / L. Further, the optimal preparation conditions of sodium alginate SA and carboxymethyl chitosan CMCS-based gel beads CMCS / SA / TPYMFP are explored. When the SA concentration is 1.5% (w / v), the CMCS concentration is 0.5% (w / v), and the CaCl2 concentration is 1% (w / v), the polypeptide encapsulation rate is increased to 98.26% ± 0.25%. It is verified that the albumin polypeptide gel beads have good pH response characteristics, and efficient protection and intestinal target delivery of the sarcopenia inhibitory peptide are realized. The albumin polypeptide gel beads are applied to preparation of a product for treating or preventing sarcopenia, or in preparation of a related product for increasing muscle mass and strength.

The invention discloses an ACE (angiotensin converting enzyme) inhibitory peptide with antihypertensive activity and application thereof, and belongs to the technical field of active peptide biology, amino acid sequences of the ACE inhibitory peptide are EYPVK and SYPVK, the two peptides are obtained through module replacement design, the ACE inhibitory activity of the two peptides is remarkably improved compared with that of an original peptide LYPVK, IC50 values are respectively reduced to 14.82 + / -0.82 mu M and 12.83 + / -0.79 mu M from 117.14 + / -1.40 mu M, and the inhibitory activity is improved by 13.5% and 25.1%. Molecular simulation analysis shows that the interaction force between the two and ACE is stronger, and a potential modular effect exists between sequences. Besides, the polypeptide has remarkable blood pressure lowering activity on human umbilical vein endothelial cells, plays a role by regulating release of NO and ET-1, has the activity superior to that of original peptides, has the advantages of good digestive enzyme stability, small molecular weight and good water solubility, and is suitable for developing related products for lowering blood pressure.

The application discloses a flagellum inhibiting peptide of pseudomonas aeruginosa and a preparation method and application thereof, and the sequence of the flagellum inhibiting peptide is Lys-Ile-Gly-Leu-Phe-Arg-Trp-Arg. The synthetic inhibiting peptide has a time-dependent self-assembly ability, can gradually evolve from scattered granular into filamentous structure, and finally forms a stable net-like morphology. The synthetic inhibiting peptide can significantly inhibit the flagellum motility of PAO1 and other strains of pseudomonas aeruginosa, and has synergistic antibacterial activity when combined with allicin, ciprofloxacin, meropenem, levofloxacin, polymyxin B and the like. Moreover, the synthetic inhibiting peptide has obvious bacteriostatic and healing-promoting effects on burn wound infection.

The invention relates to the technical field of polypeptide synthesis, discloses a semaglutide large-fragment coupling process based on an SPPS-LPPS mixing method, and aims to solve the problems that an SPPS fragment is easy to fold and the LPPS coupling efficiency is low when semaglutide is synthesized by an existing SPPS-LPPS mixing method. SPPS is adopted for solid-phase synthesis of a semaglutide 1-21 site fragment I and a semaglutide 22-31 site fragment II, and the fragment quality is guaranteed through optimization of a solid-phase carrier, staged conformation washing and differential activation; according to the method, peptide chain folding and activating agent hydrolysis can be inhibited, the coupling efficiency and the fragment utilization rate can be improved, the purity of a coupling intermediate can be guaranteed, meanwhile, the process stability and economical efficiency can be enhanced, and the industrial production requirements of semaglutide can be met.

The invention belongs to the technical field of biological medicines and bioactive peptides, and relates to a xanthine oxidase inhibitory peptide derived from goat milk protein and application thereof. The amino acid sequence of the xanthine oxidase inhibitory peptide is as shown in SEQ ID NO. 1. The xanthine oxidase inhibitory peptide can be used for preparing a product for inhibiting xanthine oxidase or a product for regulating and controlling the uric acid level in a human body. The XOD regulation active peptide provided by the invention is safe in source and clear in structure, can be applied to the field of functional food or nutrition intervention, and provides a safe and natural active substance basis for diet regulation of hyperuricemia and related metabolic diseases.

The invention relates to a preparation method of a rice bran protein ACE inhibitory peptide, and belongs to the technical field of bioactive peptide preparation. The preparation method comprises the following steps: extracting rice bran protein from defatted rice bran, carrying out step-by-step enzymolysis by using alkaline protease and papain to obtain a rice bran protein ACE crude peptide solution, centrifuging, carrying out ultrafiltration by using a 3kDa ultrafiltration tube, and purifying by using gel chromatography to obtain the rice bran protein ACE inhibitory peptide. The process is simple and efficient, the cost is controllable, the obtained ACE inhibitory peptide not only has high ACE inhibitory activity, but also has high oxidation resistance, is rich in various bioactive amino acids, can be used for efficiently preparing active peptide with strong antihypertensive potential, and provides an ideal raw material for developing novel antihypertensive food, medicine and health care products.

The invention relates to the technical field related to microcapsules, in particular to a preparation method of a wheat alpha-glucosidase inhibitory peptide microcapsule, which comprises the following steps: by taking wheat vital gluten as a raw material, carrying out enzymolysis by alkaline protease to obtain alpha-glucosidase inhibitory peptide, and then carrying out enzymolysis by adopting a sodium alginate-chitosan composite wall material system to obtain the wheat alpha-glucosidase inhibitory peptide microcapsule. By optimizing key parameters such as the core-wall ratio of 1: 2.632, the calcium chloride concentration of 2.48% and the curing time of 31.83 min, the double-layer microcapsule with the pH response characteristic is prepared by an ionic gel method. The embedding rate of the prepared microcapsule reaches 78.26%, the 2-hour release rate in simulated gastric juice (pH 2.0) is smaller than or equal to 21.38%, the 4-hour accumulative release rate in simulated intestinal juice is larger than or equal to 84.98%, and stomach protection and intestinal targeted release of the active peptide are achieved; meanwhile, the peptide loss rate of the product under the storage condition of 4 DEG C is less than or equal to 11.13%, the loss rate in the environment with the pH value of 2.0 is only 12.72%, and the stability of the active peptide is remarkably improved. The obtained product can effectively protect the activity of the alpha-glucosidase inhibitory peptide and improve the bioavailability of the alpha-glucosidase inhibitory peptide, and a new scheme is provided for developing functional hypoglycemic food.

This invention relates to a pufferfish TRPV1 inhibitory peptide, its preparation method, and its application. The amino acid sequence of the peptide is LDIF. The preparation method includes: 1. Enzymatically hydrolyzing pufferfish skin, then inactivating the enzyme, and screening for peptides with a molecular weight not greater than 1 kDa from the hydrolysate, followed by freeze-drying to obtain the pufferfish skin enzymatic hydrolysate peptide; 2. Performing mass spectrometry analysis on the pufferfish skin enzymatic hydrolysate peptide, using mass spectrometry analysis software, and selecting multiple non-repeating peptide sequences based on the criteria of confidence level -10lgP > 20 and amino acid count < 10; 3. Molecularly docking the selected peptide sequences with the TRPV1 receptor using software to select peptide sequences with strong binding affinity to the TRPV1 receptor; 4. Solid-phase synthesis of the selected peptide sequences to obtain the peptide LDIF. This invention uses pufferfish skin as raw material to obtain a peptide with good inhibitory effect on TRPV1, which can be used to prepare skin care products for soothing sensitive skin.

The invention discloses a walnut source DPP-IV inhibitory peptide as well as a preparation and screening method and application thereof. The walnut source DPP-IV inhibitory peptide comprises FPAG and / or LPSYQPTP, the preparation and screening method comprises the following steps: (1) adding walnut protein powder into deionized water, and fully dissolving to obtain a walnut protein solution; (2) adding hydrolyzed compound protease into the walnut protein solution for enzymolysis to obtain walnut protein hydrolysate freeze-dried powder; (3) re-suspending the walnut protein hydrolysate freeze-dried powder in deionized water, and performing ultrafiltration separation by using an ultrafiltration membrane with the molecular weight cutoff of 1kDa to obtain a component F1; step (4), performing peptide fragment sequence identification on the obtained F1 component through peptidomics; and step (5), screening from peptide fragment sequences obtained by identification through a bioinformatics technology. The walnut source DPP-IV inhibitory peptide screened by the invention can be used for preparing a medicine or food with a DPP-IV inhibition function, so that the problems that the existing walnut source DPP-IV inhibitor has many side effects and the like are solved.

This disclosure provides peptide aptamers, comprising one or more inhibitory amino acid sequences, that block human Cav3.2 T-type calcium channel activity and nociceptive dorsal root ganglion (DRG) neuron excitation. Also provided are pharmaceutical compositions comprising the peptide aptamers, nucleic acid constructs encoding the peptide aptamers, and methods of treatment comprising administering the peptide aptamers.

This application relates to a source-aware activity ranking-based method for screening DPP-IV repressive peptides, comprising: constructing a training dataset containing positive samples and at least three levels of negative samples; extracting multimodal features of peptides, including at least sequence deep semantic embedding features and pocket structure features; explicitly aligning the above features using a cross-attention mechanism to generate fusion features; inputting the fusion features into the classification branch and ranking branch of a decoupled prediction architecture, outputting classification probability and activity ranking score respectively, wherein the ranking branch uses an independent ranking model and is trained based on preference pairs constructed from data within the same assay source; and performing virtual screening output by combining classification probability, activity ranking score, multidimensional confidence judgment, and ADMET safety screening results. This application achieves structurally interpretable characterization of substrate-enzyme binding modes and improves the statistical significance and generalization stability of peptide activity ranking under cross-laboratory batch effects.

This invention discloses an ACE-inhibiting peptide, its screening method, and its application, relating to the field of bioactive peptide technology. The amino acid sequence of the ACE-inhibiting peptide is HIIARPH, LRLKE, SFR, or REVDKPF, exhibiting excellent ACE-inhibiting activity, good cell repair and protection capabilities, and the ability to reduce eye bag volume. It can be applied to skincare products with effects such as skin barrier repair and protection, and improvement of dark circles.

This invention discloses a method for screening pancreatic lipase inhibitory peptides based on machine learning, relating to the fields of bioinformatics and food science. The method includes the following steps: dataset construction and three-dimensional peptide structure characterization, statistical-based feature screening, outlier removal based on a dual-model consensus mechanism, feature recursive elimination and physicochemical significance optimization, data augmentation based on Gaussian noise injection, and final prediction model construction. This invention effectively solves the problems of insufficient feature representation, high noise interference, and weak model generalization ability in existing screening methods through multi-dimensional feature characterization, rigorous outlier cleaning, and data augmentation strategies for small samples. It can quickly and accurately screen highly active pancreatic lipase inhibitory peptides from massive peptide sequences, providing an efficient computational tool for the development of functional foods and lipid-lowering drugs.

The application belongs to the technical field of biological medicine, and particularly relates to a cell penetration inhibitory peptide and application thereof in breast cancer. Specifically, aiming at the interaction between circHIF-1alpha (11, 12) and IGF2BP2, a novel compound named cell penetration IGF2BP2 inhibitory peptide (IIP) is designed to intervene, so as to inhibit the energy metabolism re-regulation and tumor progression of breast cancer. The application first discloses a new use of IIP as an inhibitor of circHIF-1alpha (11, 12). In-vitro experiments prove that IIP can significantly inhibit the energy metabolism reprogramming and tumor progression of breast cancer cells. In summary, the application provides an innovative breast cancer treatment method based on the interaction between circRNA and protein, and successfully intervenes the disease process of breast cancer through the design and application of IIP, which opens up a new direction and possibility for the development of breast cancer treatment.

The invention discloses a multifunctional active peptide from mackerel viscera and application of the multifunctional active peptide. The mackerel viscera extract is prepared by adopting a single exogenous enzyme hydrolysis method, the extract has small molecule peptides with ACE inhibitory activity, three ACE inhibitory peptides are obtained by further identification and screening, the amino acid sequences are respectively GPPVPGP, GPMGPMGP and SPGPVGMP, and the half inhibitory concentration IC50 values of the ACE inhibitory peptides are respectively 80.84 + / -1.12 mu g / mL, 177.41 + / -3.26 mu g / mL and 163.25 + / -3.46 mu g / mL. Wherein the heptapeptide GPPVPGP with the optimal activity also has the function of removing DPPH free radicals and hydroxyl free radicals, and can be used for adjuvant therapy for reducing hypertension or applied to other fields.

The invention discloses a miichthys miiuy ACE inhibitory peptide as well as a preparation method and application thereof, and belongs to the technical field of ACE inhibitory peptides. The ACE inhibitory peptide of the miichthys miiuy provided by the invention comprises an amino acid sequence as shown in SEQ ID NO. 1, SEQ ID NO. 3, SEQ ID NO. 5 or Asp-Gln-Gly. The ACE inhibitory peptide with the best activity is prepared and purified by taking miichthys miiuy meat as a raw material and taking the ACE inhibition rate as an index. The influence, antioxidant activity and mechanism of the ACE inhibitory peptide on blood pressure regulation factors are researched from the chemical level, the cellular level and computer simulation, the novel ACE inhibitory peptide is found, and a theoretical basis is provided for ocean resource high value.

This invention belongs to the field of food biotechnology and bioactive peptides, and specifically relates to a cottonseed protein-derived ACE-inhibiting peptide, its screening, modification methods, and applications. The screening method of this application includes four core steps: virtual enzymatic library construction, multi-stage computer filtering, molecular docking screening, and in vitro activity verification, obtaining 194 high-confidence candidate peptides. Four cottonseed protein-derived peptides (SYF, DIF, IAF, and RFY) with in vitro ACE-inhibiting activity were verified, all exhibiting mixed ACE-inhibiting activity, with DIF showing the strongest inhibitory activity. Molecular dynamics simulations confirmed the structural stability of the ACE-DIF complex. A modified peptide FIF was obtained through a dipeptide module substitution strategy, with an IC50 value of [missing information]. 50 The activity was significantly reduced, approximately 3.7 times that of the parent peptide DIF, and the inhibition type changed from mixed to competitive. This invention provides a new approach for the development of natural antihypertensive functional peptides and the high-value utilization of plant protein resources.

This invention discloses a crayfish head protein peptide with uric acid-lowering effect and its application, belonging to the field of biotechnology. The amino acid sequence of the crayfish head protein peptide is shown in any one of SEQ ID NO. 1-4. This invention uses ultrasonic and microwave technology to assist protein hydrolysis, prepares xanthine oxidase inhibitory peptides from crayfish heads, explores the material basis of its activity, and studies its mechanism of action, laying a theoretical foundation for the high-value utilization of crayfish processing by-products and the development of food-derived xanthine oxidase inhibitors.

The present application relates to a kind of preparation method and application of egg yolk polypeptide with ACE inhibitory activity, the method comprises: Q1.degreased egg yolk powder is dissolved in appropriate amount of water, adjust pH to 6~8;Q2.50~60 ℃, pH=7‑8 under the condition of adding alkaline protease or flavour protease is carried out enzymolysis 1.5~2.5h, then enzyme is killed, and the egg yolk hydrolysate is obtained.The present application not only uses step-by-step enzymatic hydrolysis to prepare high-activity ACE inhibitor, and using the method of bioinformatics, 5 ACE inhibitory peptides (KFIPL, KFLPGY, KFLPTF, ATPFGKL, KLPDMILY) with high activity are screened and identified, and in order to solve the problem of polypeptide instability after sterilization in functional beverage, CMC and GG are used as stabilizer, and the problem of enzymatic polypeptide in functional beverage is solved.

The invention belongs to the technical field of plant peptide preparation, and particularly relates to a preparation method of pea oligopeptide and application of the pea oligopeptide in the aspect of reducing blood sugar. The pea oligopeptide is prepared by taking pea protein as a raw material through an enzymolysis method, core peptide fragments VA, FPW and WPF of the pea oligopeptide are obtained through further identification on the basis, and VA, FPW and WPF are screened and confirmed as potential inhibitory peptides targeting DPP-IV by combining molecular docking and molecular dynamics simulation technologies. Besides, the DPP-IV inhibition rate of the core peptide fragment is further determined through an in-vitro experiment, and the FPW and the WPF are confirmed to be the core peptide fragment with efficient DPP-IV inhibition potential and have relatively good structural stability by combining cell experiment analysis, so that theoretical support is provided for the hypoglycemic effect of the pea peptide core peptide fragment, and a foundation is laid for development of hypoglycemic nutritional and healthy products.

The application discloses a sciaenops ocellatus TRPV1 inhibiting peptide, a preparation method and application, belongs to the polypeptide field, and the amino acid sequence of the sciaenops ocellatus TRPV1 inhibiting peptide is RLF.The sciaenops ocellatus TRPV1 inhibiting peptide, the preparation method and the application take the skin of sciaenops ocellatus as starting raw material, and the amino acid sequence of the sciaenops ocellatus TRPV1 inhibiting peptide is successfully obtained through a specific process.Experiment verification shows that the prepared sciaenops ocellatus TRPV1 inhibiting peptide shows excellent inhibiting effect on TRPV1.The inhibiting peptide can be used for preparing a TRPV1 antagonist, the antagonist can play an anti-inflammatory regulation role through multiple channels, and can effectively down-regulate skin microvascular hyperreactivity.

The present application relates to the field of biotechnology, and more particularly to an inhibitory peptide targeting p53 protein and application thereof. The present application uses IDProMat to design and obtain the inhibitory peptide targeting p53 protein according to the core binding site of the binding interface of the p53 protein core domain and ASPP2, TSPYL5, iASPP and the like; the inhibitory peptide can bind to p53 protein, competitively block the interaction between E3 ubiquitin ligase COP1 and p53, inhibit the ubiquitination degradation of p53, restore the anticancer function of p53, and has good biological safety and metabolic stability, and is expected to be used for clinical treatment of ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer and the like.

The present application relates to the field of biotechnology, and more particularly to a cassava peptide for inhibiting alpha-glucosidase activity and a preparation method thereof. The present application recovers cassava starch wastewater protein by acid precipitation method, and obtains high-activity alpha-glucosidase inhibitory peptides by heat and ultrasonic pretreatment of cassava protein to assist enzymatic hydrolysis. The peptide sequence is analyzed, the alpha-glucosidase inhibition type is determined, four cassava peptides with alpha-glucosidase activity are obtained, and their high alpha-glucosidase inhibitory activity in vivo and in vitro is verified. A new alpha-glucosidase inhibitory peptide is given, the blank in the prior art is overcome, and a new idea for high-value utilization of cassava processing wastewater is provided.

This invention utilizes a machine learning model to analyze the crystal structure of the PEDV Nsp5 protein. Through virtual peptide screening technology, a peptide sequence with potential affinity for the target protein, YKKLHK(162860), was artificially synthesized in a solid phase. Using artificially expressed PEDV Nsp5 protein, the peptide was screened using an ELISA assay. The affinity constant between the peptide and the target protein was determined using surface plasmon resonance (SPR) assays. The cytotoxicity of peptide 162860 was tested using a CCK-8 assay kit. Its inhibitory activity against viral infection was tested using quantitative real-time PCR and indirect immunofluorescence assays. The results showed that the 162860 sequence significantly inhibited PEDV infection.